Interview: Christopher Tsai, Chairman, Bionet, Taiwan
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
Organization Activities
BIONET Corp. was first established in 1999 as the pioneer company in the field of stem cell application in Taiwan as well as in Asia. BIONET has focused: “Stem Cell Therapy” and “Genetic Testing”. In 2007, BIONET completed initial public offering (TPO: 1784) and became the first publicly traded company in the stem cell and genetic industry of Taiwan. Furthermore, in 2012, Genesis Genetics Asia Corp. (GGA), a subsidiary of BIONET, made its IPO (TPO: 4160) as Taiwan’s first public company specialized in both genetic testing and scientific informatics. BIONET is the largest enterprise that the penetration rate is up to 50% for cell therapy and genetic engineering industry in Taiwan.
Contact Information
Address: No.28, 36 Ln., Xinhu 1st Rd.,
Neihu Dist., Taipei City 11494
Taiwan
Phone: +886-2-2795-1777, Monday to Friday, 9am-6pm CST (UTC+8)
Toll-free: 0800-800-018
Email: service@babybanks.com
Website: www.babybanks.com
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
Nutrarex Biotech is a Taiwanese private label contract manufacturer of functional supplements, exclusively representing a number of cutting-edge raw materials from Europe, the US, and Japan. Stanley Huang is the…
In an effort to enhance trade and cooperation with other countries in the region and reduce dependency on mainland China, in 2016 Taiwan’s government introduced the New Southbound Policy (NSP).…
Within Taiwan’s evolving medical device sector, many innovative startups are exploring breakthrough ideas which are sparking global interest and attention – iXensor being a chief example. The company’s patented technology…
Mark Yang, CEO of GaleMed, elaborates on the medical device manufacturer’s transition from a privately-owned company to being acquired by private equity firm Nexus Point Capital. Yang goes on to…
United Biomedical, Inc. (UBI) is dedicated to the discovery, development, and commercialization of immunotherapies & vaccines for chronic and infectious diseases and is passionate about delivering science-driven innovation with platform…
James Chiu, GM of Fresenius Kabi Taiwan, discusses the affiliate’s portfolio offering of parenteral and enteral nutrition in Taiwan as well as its move towards biosimilars. In addition, Chiu highlights…
Shuhei Sekiguchi, recently-appointed managing director of Janssen Taiwan, discusses how his vast experience in marketing and sales will help him in this new role, Janssen´s market outlook for Taiwan, its…
The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each…
G-SYN Biomedical Technology is a company dedicated to resolving problems occurring from cell hypoxia. Dieter Chang, the company’s founder introduces the firm, why they decided to focus on hypoxia, their…
Philip Chen, chairman of the Taipei Exchange, discusses the capital market condition, elaborates on the significance of biotech, and shares the competitive advantages of innovation companies listing on TPEx. Chen…
Danny Liao, CEO of Taiwanese diagnostics firm Skyla discusses the reason behind splitting from parent company Lite-On, the thinking behind a move from information technology (IT) into medical diagnostics and…
The Southern Taiwan Science Park (STSP)’s Chen-Kang Su discusses how STSP has played a key role in bringing innovation to Taiwan, how collaborations between academic institutions and industry are helping…
See our Cookie Privacy Policy Here